Akums Drugs hits upper limit on entering into exclusive master sales agreement with Caregen
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Akums Drugs & Pharmaceuticals is currently trading at its upper limit of Rs. 580.95, up by 27.65 points or 5.00% from its previous closing of Rs. 553.30 on the BSE.
The scrip opened at Rs. 536.15 and has touched a high and low of Rs. 580.95 and Rs. 527.00 respectively. So far 109506 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 527.00 on 19-Nov-2024.
Last one week high and low of the scrip stood at Rs. 639.00 and Rs. 527.00 respectively. The current market cap of the company is Rs. 9143.80 crore.
The promoters holding in the company stood at 75.26%, while Institutions and Non-Institutions held 14.58% and 10.16% respectively.
Akums Drugs and Pharmaceuticals has entered into an exclusive Master Sales Agreement with Caregen Company, (Caregen), a leading South Korean company in Nutraceuticals segment. Akums has been granted the exclusive rights to sell certain Caregen products range, in India, during the term of the agreement. Further the company shall also undertake the packaging, marketing and selling of Caregen’s line of bulk product under the Caregen’s trademark or Akums’s trademark or of Akums’s Clients trademark.
Caregen is a global leader in peptide research and development and a global biotechnology company based in South Korea that has commercialized the unlimited expandability of its patented peptides as many innovative products.
Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
